Belite Bio, Inc Rings the Nasdaq Stock Market Opening Bell in Celebration of its IPO

Belite Bio, Inc (Nasdaq: BLTE) is a clinical stage biopharmaceutical drug development company, targeting untreatable age-related metabolic diseases, including macular degeneration. Belite’s lead pipeline of novel therapies, includes LBS-008, which is focused on meeting the unmet needs of patients suffering from progressive vision loss ultimately leading to blindness caused by Stargardt disease, an inherited juvenile form of macular degeneration and dry AMD. Belite Bio visits Nasdaq’s MarketSite in Times Square in celebration of its listing. In honor of the occasion, Belite’s CEO, Tom Lin, rings the Opening Bell.